Guardant Health, Inc. (GH) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in Palo Alto, CA, United States. Der aktuelle CEO ist Helmy Eltoukhy.
GH hat IPO-Datum 2018-10-04, 1,999 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $11.33B.
Guardant Health, Inc. is a precision oncology company that develops and provides innovative blood-based liquid biopsy tests and analytics for cancer detection and treatment. The company offers a portfolio of products including Guardant360 and its variants for advanced-stage cancer patients, GuardantINFORM for clinical genomic research, and LUNAR-2 for early colorectal cancer detection, as well as GuardantConnect, a software platform connecting patients with relevant clinical trials. Additionally, Guardant Health provides development services to biopharmaceutical companies and medical institutions, including companion diagnostic development, clinical trial support, and testing solutions. Headquartered in Redwood City, California, the company operates globally and serves the oncology market through its comprehensive suite of diagnostic and data analytics offerings.
